Effect of oral semaglutide on energy intake, appetite, control of eating and gastric emptying in adults living with obesity: A randomized controlled trial
Assessed by RV012 · Lecturer (Teaching & Research)
Assessed on 30 Oct 2025
OverallReviewer's overall integrity assessment, derived from all research questions No concerns
DOI 10.1111/dom.15802 (opens in new tab)
Resource ripekg:research-integrity-assessment/RIPEA312D0E8F4C1164EF
5 Research Questions · 2 Evidence Items
Q1.1 — Does the study have an associated retraction?
Rationale: Nothing on the website either
Q1.2 — Does the study have an associated expression of concern or other relevant post-publication notice?
Rationale: No concerns, but note it is a recent paper
Q1.3 — Do other studies by the research team highlight causes for concern?
Rationale: No concerns
Q2.2 — Are there concerns relating to the timing or absence of study registration?
Rationale: No concerns
Supporting Evidence (2)
Clinical Trial RegistrationSource: Clinical trial registry (e.g. ClinicalTrials.gov, ISRCTN)
Registration ID: NCT05236517
Registry: ClinicalTrials.gov
Registry Link: https://clinicaltrials.gov/study/NCT05236517 (opens in new tab)
Registration Date: 04-02-2022
Prospective:Whether the trial was registered before participant recruitment began Yes
Assessment Rationale:How INSPECT-AI determined the prospective registration status by comparing dates Registration date is on or before LLM recruitment start date.
Study Design EvidenceDates and timelines extracted by INSPECT-AI from the publication text
Recruitment Start: 08-02-2022
Recruitment Start Rationale:INSPECT-AI's reasoning for how it identified the recruitment start date Study design: 'from 8 February to 7 November 2022' indicates recruitment started on 08-02-2022.
Recruitment End: N/A
Recruitment End Rationale:INSPECT-AI's reasoning for how it identified the recruitment end date No explicit recruitment_finish date found.
Study End: 07-11-2022
Study End Rationale:INSPECT-AI's reasoning for how it identified the study end date Study design: 'from 8 February to 7 November 2022' indicates study ended on 07-11-2022.
Overall — What is the overall integrity assessment of the study?
Rationale: No concerns